Tilly H, et al. - In patients with previously untreated diffuse large B-cell lymphoma, researchers assessed safety as well as preliminary activity of polatuzumab vedotin combined with rituximab or obinutuzumab and cyclophosphamide, doxorubicin, and prednisone (CHP) in this open-label, non-randomized study. This investigation was conducted at 11 hospitals and health centers in the US and France and composed of a phase 1b dose escalation and a phase 2 dose expansion. Findings revealed that polatuzumab vedotin with R-CHP or G-CHP had a safety profile that was, as expected, manageable and encouraging preliminary clinical activity in newly diagnosed diffuse large B-cell lymphoma.